CALLA Positive Lymphoblastic Leukemia, also known as CALLA+ ALL, is a type of acute lymphoblastic leukemia (ALL) characterized by the presence of common acute lymphoblastic leukemia antigen (CALLA) on the surface of lymphoblasts. It is classified as a subtype of B-cell ALL based on the presence of certain genetic and molecular abnormalities.
Lymphoblastic leukemia refers to a cancer of the bone marrow and blood cells where immature lymphocytes, known as lymphoblasts, rapidly multiply and crowd out normal cells. In CALLA+ ALL, these lymphoblasts express the CALLA antigen, which is a particular protein found on the surface of the cancerous cells. The presence of CALLA antigen allows for the identification and classification of this specific subtype of ALL.
CALLA+ ALL is more commonly seen in children and adolescents, although it can affect individuals of any age. The exact cause of this type of leukemia is still unknown, but certain risk factors, such as genetic mutations, exposure to certain chemicals or radiation, and immune system disorders, may play a role in its development.
Treatment for CALLA+ ALL typically involves a combination of chemotherapy, radiation therapy, and stem cell transplantation, depending on the age, health, and response to initial treatment of the patient. Prognosis and survival rates vary depending on the patient's age, overall health, genetic abnormalities, and response to treatment.
In summary, CALLA Positive Lymphoblastic Leukemia is a subtype of acute lymphoblastic leukemia characterized by the presence of the CALLA antigen on the surface of lymphoblasts. It primarily affects children and requires aggressive treatment to improve prognosis and survival.
